Document Detail


Increased FDG uptake in association with reduced extremity fat in HIV patients.
MedLine Citation:
PMID:  23041595     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: HIV lipodystrophy - characterized by peripheral lipoatrophy, with or without central fat accumulation - confers increased metabolic risk. However, the functional activity of HIV lipodystrophic tissue in relation to metabolic risk has yet to be fully explored in vivo through the use of non-invasive imaging techniques. This study assesses the relationship between FDG uptake in various fat depots and metabolic/immune parameters among subjects with HIV lipodystrophy.
METHODS: Lipodystrophic men on antiretroviral therapy underwent whole-body (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography scans and detailed metabolic/immune phenotyping.
RESULTS: FDG uptake in the subcutaneous adipose tissue (SAT) of the extremities (mean standardized uptake value [SUV] of the arm and leg SAT) was found to correlate with the degree of peripheral lipoatrophy (r=0.7; P=0.01). Extremity SAT FDG uptake was positively associated with homeostasis model assessment of insulin resistance (HOMA-IR; r=0.6; P=0.02) and fasting hyperinsulinaemia (r=0.7; P=0.01), while fat percentage of extremities was not. Furthermore, extremity SAT FDG uptake was significantly associated with CD4(+) T-cell count (r=0.6; P=0.05). In multivariate modelling for HOMA-IR, extremity SAT FDG uptake remained significant after controlling for body mass index and tumour necrosis factor-α (R(2) for model =0.71, P=0.02; SUV in the extremity SAT β-estimate 12.3, P=0.009).
CONCLUSIONS: In HIV lipodystrophic patients, extremity SAT FDG uptake is increased in association with reduced extremity fat and may contribute to insulin resistance. Non-invasive assessments of in situ inflammation using FDG-PET may usefully complement histological and gene expression analyses of metabolic dysregulation in peripheral fat among HIV-positive patients.
Authors:
Martin Torriani; Markella V Zanni; Kathleen Fitch; Eleni Stavrou; Miriam A Bredella; Ruth Lim; Aaron M Cypess; Steven Grinspoon
Related Documents :
23235085 - Adherence with screening guidelines for hepatitis c testing among hiv-infected patients.
23114115 - Anaemia in hiv-infected children: severity, types and effect on response to haart.
25057045 - The intestinal microbiota, microbial translocation and systemic inflammation in chronic...
23111095 - Hepatitis b virus (hbv) reactivation in rheumatic patients with hepatitis core antigen ...
19780945 - Hiv-hcv co-infected patients with low cd4+ cell nadirs are at risk for faster fibrosis ...
18318825 - Virological and clinical implication of core promoter c1752/v1753 and t1764/g1766 mutat...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-10-05
Journal Detail:
Title:  Antiviral therapy     Volume:  18     ISSN:  2040-2058     ISO Abbreviation:  Antivir. Ther. (Lond.)     Publication Date:  2013  
Date Detail:
Created Date:  2013-03-28     Completed Date:  2013-09-13     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9815705     Medline TA:  Antivir Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  243-8     Citation Subset:  IM    
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT01098045
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abdominal Fat / metabolism,  pathology
Body Composition
Extremities / pathology*
Fluorodeoxyglucose F18 / diagnostic use*,  metabolism
HIV-Associated Lipodystrophy Syndrome / diagnosis*,  immunology,  metabolism
Humans
Male
Middle Aged
Multimodal Imaging*
Positron-Emission Tomography*
Subcutaneous Fat / metabolism,  pathology*
Tomography, X-Ray Computed*
Grant Support
ID/Acronym/Agency:
1 UL1 RR025758-01/RR/NCRR NIH HHS; 1UL1 RR025758/RR/NCRR NIH HHS; 2P30AI060354/AI/NIAID NIH HHS; F32 DK085969/DK/NIDDK NIH HHS; F32 DK085969/DK/NIDDK NIH HHS; K23 DK081604/DK/NIDDK NIH HHS; K23 DK081604/DK/NIDDK NIH HHS; K24 DK064545/DK/NIDDK NIH HHS; K24 DK064545/DK/NIDDK NIH HHS; M01-RR-01066/RR/NCRR NIH HHS; P30 AI060354/AI/NIAID NIH HHS; P30DK0440561/DK/NIDDK NIH HHS; UL1 RR025758/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0Z5B2CJX4D/Fluorodeoxyglucose F18
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Detection of RD-114 virus by a reverse transcriptase assay based on product enhancement.
Next Document:  Synovial fluid eosinophilia: a case series with a long follow-up and literature review.